Long-term efficacy and safety of fingolimod in paediatric multiple sclerosis patients: analysis of PARADIGMS study up to 6 years of treatment

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2022
This article has no abstract
Epistemonikos ID: 9b7f824023ab0164896c4701d6b76181b71bc0d6
First added on: Apr 30, 2026